Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.43 |
| ▸ | GABRP | O00591 | 3/20 | 0.43 |
| ▸ | GABRD | O14764 | 3/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.43 |
| ▸ | GABRE | P78334 | 3/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30433741 | 1.00 | MAPK1 (0.44) | MAPK1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL18725442 | 0.84 | MAPK1 (0.44) | MAPK1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL21622928 | 0.84 | MAPK1 (0.44) | MAPK1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL19835436 | 0.81 | MAPK1 (0.50) | MAPK1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL16318862 | 0.80 | MAPK1 (0.46) | MAPK1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL28475255 | 0.80 | KDM4E (0.42) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL21873493 | 0.78 | LCK (0.53) | MAPK1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL30031450 | 0.78 | MAPK1 (0.47) | MAPK1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL3936135 | 0.78 | MAPK1 (0.47) | MAPK1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL3244089 | 0.78 | MAPK1 (0.47) | MAPK1GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552777-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20240376079-A1 | Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use Thereof | ENANTA PHARM INC (US) | 2024-11-14 | — | — | US | disclosed |
| US-12018017-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018017-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3621615-B1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3621615-B1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-06-08 | — | — | US | disclosed |
| CN-110869017-B | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | 英安塔制药有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-10683279-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3621615-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| CN-110869017-A | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | 英安塔制药有限公司 | 2020-03-06 | — | — | CN | disclosed |
| WO-2020011209-A1 | IMMUNOSUPPRESSIVE AGENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2020-01-16 | — | — | WO | disclosed |
| WO-2020011209-A1 | IMMUNOSUPPRESSIVE AGENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2020-01-16 | — | — | WO | disclosed |
| EP-3156397-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-20180327388-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-11-15 | — | — | US | disclosed |
| WO-2018209354-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3156397-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552777-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | AIFM1, BAD, IRAK1 | MAPK1 46/4885GABRA1 4689/4885GABRG2 4865/4885 |
| US-20240376079-A1 | Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use Thereof | BAD, CASP1, BAX | MAPK1 71/4885GABRA1 4617/4885GABRG2 4799/4885 |
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | MAPK1 708/4885GABRA1 325/4885GABRG2 1032/4885 |
| US-12018017-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | MAPK1 71/4885GABRA1 4617/4885GABRG2 4799/4885 |
| US-20180327388-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, CASP1, BAX | MAPK1 71/4885GABRA1 4617/4885GABRG2 4799/4885 |
| US-10683279-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | MAPK1 71/4885GABRA1 4617/4885GABRG2 4799/4885 |
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, CASP1, BAX | MAPK1 71/4885GABRA1 4617/4885GABRG2 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.